Intensive Motivational Interviewing for Methamphetamine Dependence
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01071356|
Recruitment Status : Completed
First Posted : February 19, 2010
Last Update Posted : September 27, 2013
|Condition or disease||Intervention/treatment||Phase|
|Methamphetamine Dependence||Behavioral: Intensive Motivational Interviewing Behavioral: Single session of Motivational Interviewing||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||217 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Intensive Motivational Interviewing for Methamphetamine Dependence|
|Study Start Date :||February 2009|
|Actual Primary Completion Date :||October 2012|
|Actual Study Completion Date :||October 2012|
Experimental: 9 sessions of Motivational Interviewing
Respondents received 9 1-hour sessions of Motivational Interviewing therapy concurrent with outpatient drug treatment.
Behavioral: Intensive Motivational Interviewing
Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
Active Comparator: 1 session of Motivational Interviewing + 8 sessions nutrition
Respondents received one 1.5-hour session of Motivational Interviewing therapy at the outset of entering outpatient drug treatment.
|Behavioral: Single session of Motivational Interviewing|
- Methamphetamine positive urine screens [ Time Frame: Weekly while in treatment (9 weeks) and 4 and 6 month follow up ]
- Addiction Severity Index [ Time Frame: Baseline, 2-,4-, and 6-month follow up ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01071356
|United States, California|
|Alcohol Research Group|
|Emeryville, California, United States, 94608|
|Principal Investigator:||Douglas Polcin, Ed.D.||Alcohol Research Group / Public Health Institute|